Introduction: Focal adhesion kinase (FAK) plays a significant role in cancer cell survival signaling and is overexpressed in various malignancies, including lung cancer. Previous studies suggest that FAK overexpression is an independent factor predicting poor prognosis in non-small-cell lung cancer (NSCLC). The aim of this study is to confirm these findings specifically in stage I NSCLC. Methods: A retrospective tissue microarray (TMA) analysis of FAK protein expression by immunohistochemistry was performed in 157 surgically resected stage I NSCLC specimen and in the corresponding matched normal lung tissue. The FAK 4.47 monoclonal antibody was used for FAK immunostaining. The scoring system of triplicate tumor cores included intensity of staining plus extent of staining for a composite score that ranged from 0 to 6. The association between FAK score and survival was evaluated. Results: There were 103 stage IA and 54 stage IB patients, with mean follow-up of 5.5 years. Normal lung alveoli and interstitial tissue had mean FAK score of 0 (median score 0, range 0 to 2). Tumor samples had mean FAK score 3.1 (median score 3.5, range 0-6), with 57% of the samples having FAK score ≥ 3. Continuous FAK score was not associated with demographic data, tumor histology, or grade, nor survival in this cohort of stage I NSCLC patients. Conclusions: FAK is expressed in more than 50% of stage I NSCLC lung cancer but not in normal lung alveoli and interstitial tissue. FAK expression is not associated with survival outcome in this North American cohort.
L
ung cancer is the most common cause of death from cancer worldwide, with an estimated 1.4 million deaths in 2008. 1 The overall 5-year survival rate is less than 20%, 2 reflecting the advanced stage of the lung cancer at diagnosis in majority of patients. However, even among pathologic stage I lung cancers, outcomes vary according to specific tumor node metastasis classification, with 5-year survival between 58% and 83% at best. 3 A five-gene signature has been shown to be an independent predictor of relapse-free and overall survival among non-small-cell lung cancer (NSCLC) patients. 4 However, rapid and widespread adoption of this assay platform is limited. It is thus critical to identify biomarkers using easily reproducible assays to improve risk-stratification in stage I NSCLC for future adjuvant studies.
Focal Adhesion Kinase (FAK) is a 125 kDa protein tyrosine kinase that is overexpressed in a number of different types of solid tumors. 5, 6 FAK suppresses apoptosis in tumor cells and is critical for survival, invasion, and metastasis. [7] [8] [9] FAK has been shown to be overexpressed in colon tumors compared with normal matched samples by both immunohistochemistry (IHC) and reverse-transcriptase polymerase chain reaction (RT-PCR). 6 Recently, FAK was found to be overexpressed in lung tumors, and its higher expression correlated with nodal spread and advanced disease stages, [10] [11] [12] suggesting its important role in lung cancer progression and metastasis. Moreover, activation of FAK, along with protooncogene SRC, Rous sarcoma, promote cell migration, and adhesion in liver kinase B1 (LKB1)-deficient KRAS mutant lung tumors, a genotype associated with high propensity for nodal and distant metastases. 13 As SRC is a substrate of activated FAK, 5 there maybe a potential therapeutic role for SRC inhibitors such as dasatinib in FAK-activated NSCLC. We thus hypothesized that FAK expression may discriminate stage I NSCLC patients who are at high-risk for relapse and mortality from lung cancer. FAK expression was thus evaluated by IHC in a retrospective cohort of stage I NSCLC patients who underwent curative surgical resection.
PATIENTS AND METHODS

Patients and Tissue Samples
The Roswell Park Cancer Institute Institutional Review Board approved this retrospective project in compliance with federal, state and local requirements. All clinical and outcome patient data were de-identified. Tumor specimens and matched normal lung tissue were collected from patients who underwent surgical resection of lung cancer at Roswell Park Cancer Institute, Buffalo, NY.
Patients with small cell or mixed histologies with small cell component were excluded from this study. One-hundred and fifty seven patients diagnosed with pathologic stage I NSCLC between December 1992 and October 2008 who had sufficient tissue for this project were included in the analysis.
Median follow-up duration was 5.1 years (range 0.1-15.5 years). The American Joint Committee on Cancer staging criteria (Sixth edition) was used for all patients for uniformity of pathologic staging.
Tissue Microarrays (TMA)
TMA's were constructed from formalin-fixed paraffinembedded tissues with tumors. TMA's containing lung tumors and matched normal tissues from 161 samples were prepared with each tumor and normal core sample in triplicate. Three 0.6 mm tissue cores from formalin-fixed paraffin-embedded donor blocks were precisely arrayed into a new recipient paraffin block. Each patient had three lung tumor tissue cores on a TMA slide. 
Immunohistochemical Staining
The immunohistochemical staining was performed with FAK 4.47 antibody (Millipore#05-537). For antigen retrieval, slides were heated in the microwave for 10 minutes in citrate buffer (pH 6.0), followed by a 15 minute cooling period. Endogenous peroxidase was quenched with aqueous 3% H 2 O 2 for 10 minutes and washed with 1× phosphate-buffered saline using 0.5% Tween 20 solution. Slides were loaded on a DAKO autostainer and blocked with serum-free protein block solution (Dako #X0909) for 5 minutes and then probed with FAK primary antibody (Millipore #05-537) for 1 hour, followed by the biotinylated goat anti-mouse IgG (Jackson Immuno Research Labs, #115-065-062) for 30 minutes, then by the Elite ABC Kit (Vectastain, #PK-6200) for 30 minutes, and the DAB chromagen (Dako, #K4007) for 5 minutes. The slides were counterstained with hematoxylin.
Scoring for FAK
Slides were analyzed by two of the coauthors (L.Y. and S.P.), board-certified pathologists in a blinded and independent manner. The scoring system of triplicate tumor cores included intensity of staining (0, none; 1+, weak; 2+, moderate; 3+, strong) plus extent of staining which represented the number of cores with a positive staining (extent 0, no staining in three cores; 1, only one core had a positive staining, mild; 2, only two cores had a positive staining, moderate; 3, all three cores had the positive staining, diffuse). The composite score ranged from 0 to 6, which was equal to the sum of the average intensity and the extent of staining in the three cores. The percentage of stained cells was not used in the scoring as FAK staining was diffuse within the tumors. Patients with less than two tissue sample cores were excluded from analysis.
Statistical Methods
The associations between continuous FAK scores and clinical factors were assessed using nonparametric Spearman correlation or Kruskal-Wallis tests as appropriate. The univariate and multivariate associations of clinicopathological patient data and FAK lung tumor staining were performed using ordinary least squares regression. For further analysis, patients were dichotomized into two groups: FAK tumor score more than or equal to 3 (a group with intensity of FAK staining ≥ 1 and extent ≥2) and FAK tumor less than 3 (a group with intensity <1 and extent < 2). Contingency tables were analyzed by Fisher's Exact Test. Images taken under ×20 magnification. A, representative images of scoring system that measured intensity (0, none; 1+, weak; 2+, moderate; and 3+, strong). (B) Representative triplicate core showing extent of staining which represented the number of cores with a positive staining (extent 0, no staining in three cores; 1, only one core had a positive staining, mild; 2, only 2 cores had a positive staining, moderate; 3, all three cores had the positive staining, diffuse). In this example, the "extent" score is 3. The total FAK score including the measured intensity is 6.
Overall survival was defined as time in months between enrollment and death or last follow-up, whichever occurred first. Multivariate effects on overall survival were assessed using multivariate proportional hazards models. Associations between overall survival and stage or FAK expression were also described by Kaplan Meier curves and Log-rank tests.
Reproducibility of the scores was assessed using a set of validation scores from a second independent pathologist. Agreement between the two sets of continuous scores was assessed using the Concordance Correlation Coefficient (CCC), which ranges between −1 and +1. Higher values indicate better agreement.
14 The CCC adjusts for the probability of observing good agreement by chance alone.
p values less than 0.05 were considered statistically significant, with no adjustment for multiplicity. All analyses were obtained using SAS/STAT software, version 9.4, copyright 2012 SAS Inc. (Cary, NC). Table 1 summarizes the clinical and pathologic characteristics of patients whose tumor specimen were utilized for this study. The median age of all patients was 68 (range 46-86 years). There were 103 stage IA and 54 stage IB patients. There was no difference in terms of gender, age, histology, smoking, or alcohol use status between stage IA and stage IB patients. Stage IB patients received perioperative (neoadjvuant and/or adjuvant) systemic therapy more frequently than stage IA patients (26% versus 6%, p < 0.001). The male to female ratio was 0.91 (75 male, 82 female). Majority (90%) identified themselves as Caucasian. Current smokers comprised 33% of the group, whereas former smokers represented the majority (62%). Histologic subtype was divided into four groups: adenocarcinoma, squamous cell carcinoma, large cell, or poorly differentiated NSCLC not otherwise specified (NOS). One case of adenosquamous carcinoma was grouped under the adenocarcinoma category.
RESULTS
Clinicopathologic Characteristics
FAK Expression
The inter-pathologist agreement on the continuous patient-level FAK expression scores revealed a CCC of 0.977 (95% confidence interval [CI]: 0.970-0.984) indicating low interobserver variation. Our results showed that FAK expression was predominantly diffuse and cytoplasmic in distribution in tumor cells whereas its expression was absent in normal lung alveoli and interstitial tissue. Figure 1 shows a representative image of the range of FAK staining intensity. Most of the normal lung tissue did not express FAK, and the mean score was equal to 0 (range 0-2), as demonstrated in Figure 2 . The mean FAK score in the entire group of lung tumors was 3.13 (median 3.5, range 0-6). As expected, there was no difference in the FAK score of normal lung tissue between pathologic stage IA and stage IB patients.
Univariate comparisons of tumor FAK score as continuous variable showed no association with any of the clinicopathologic variables, including overall survival. We then dichotomized the lung tumors according to the composite FAK score: more than equal to 3 and less than 3 as the maximum FAK score found in normal alveoli was 2 which may represent a transition zone with biological relevance. Fifty seven percent of the tumors had FAK scores more than or equal to 3. The remaining 43% of tumors, in the group with FAK score less than 3, had a median score of 1.3. We also performed analysis according to a higher FAK score cutoff. Twenty-five percent of tumors had FAK scores more than or equal to 5. The median FAK score of tumors in the FAK score less than 5 group was 2.7.
FAK Score and Clinicopathologic Features
As aforementioned, univariate comparisons of tumor FAK score as continuous variable showed no association with any of the clinicopathologic variables. Using the above dichotomy in FAK scoring, correlation between FAK expression and clinicopathologic features was analyzed. As shown in Table 2 , there was no association between lung tumor FAK score of more than or equal to 3 and less than 3 with age, gender, race, smoking status, pathologic stage, histologic subtype nor histologic grade. Statistically significant correlations were established between tumor FAK score more than or equal to 5 with histology (adenocarcinoma type), gender (women), and alcohol use (never users).
FAK Score and Survival
We subsequently analyzed the relationship between FAK score and survival outcomes. The median survival of patients with lung tumor FAK score ≥ 3 was 6.3 years (95% CI: 4.6-7.4) whereas those with lung tumor FAK score less than 3 was 5.1 years (95% CI: 3.5-6.3). This difference was not statistically significant (log-rank p = 0.2). Using a higher FAK score of 5 as cutoff also did not reveal any association as well with survival. Figure 3 shows the Log-rank overall survival curve according to FAK score. In comparison, the difference in the median survival between stage IA and IB patients was not significant (5.8 years versus 5.7 years, p = 0.9). Among other clinicopathologic variables in 
DISCUSSION
This study analyzed FAK expression in stage I NSCLC and matched normal lung tissues using TMA. Our results showed that normal lung tissues did not express FAK, whereas high FAK expression can be seen even in stage I cases. This finding is important and provides rationale for investigating FAK expression in premalignant lesions as a biomarker for disease progression into invasive lung cancer. In breast cancer, FAK expression can be detected in 66% of preinvasive ductal carcinoma in situ lesions and 21% of atypical ductal hyperplasia tissues. 15 Whether FAK expression will also be expressed in premalignant lesions in the respiratory tract remains to be investigated.
One of the earliest investigations suggesting a prognostic role for FAK expression in lung cancer was led by Nishimura et al 12 who correlated the presence of phosphorylated 100 to 130 kDa proteins with regional nodal involvement and survival independent of nodal involvement in Japanese patients who underwent surgery for NSCLC. Another study demonstrated correlation between FAK overexpression and more advanced stages of disease using 153 NSCLC frozen tissues in Chinese patients. 10 The authors reported that FAK overexpression was associated with lymph node metastasis and more advanced stages of NSCLC. FAK overexpression was independently associated with worse overall survival, suggesting it as a significant prognostic factor in addition to pathologic stage. Another group evaluating FAK expression in NSCLC resected from Chinese patients also reported that FAK expression was associated with worse prognosis, higher incidence of tumor recurrence, and distant metastasis. 16 A different retrospective analysis in Chinese patients also revealed that FAK expression confers worse survival in surgically resected lung adenocarcinoma. 17 In comparison, FAK expression was not a prognostic factor in North American patients with small-cell lung cancer, as its expression did not correlate with disease stage, recurrence/progression-free survival, or overall survival. 18 Our study is the first publication to analyze FAK expression specifically in a large cohort of stage I NSCLC patients in North America. In contrast to the aforementioned studies in NSCLC, we did not detect a correlation between FAK expression and survival in our patient population. The survival curves that counterintuitively showed a trend of better survival in tumors with higher FAK scores (either ≥ 3 or ≥5) may be attributed to either random chance or true effect that warrants further investigation in this population. Indeed, a recent North American study reported in abstract form, analyzing FAK protein expression by IHC in archival tumors from 216 stage I-III NSCLC patients, revealed that FAK IHC score was higher in early stage (stage I versus stage II or stage III) tumors, particularly in adenocarcinomas and in never smokers. 19 In the adenocarcinoma cases, FAK protein overexpression correlated with better overall survival even after adjusting for stage and adjuvant therapy and was significantly higher in tumors with epidermal growth factor receptor mutations.
Our study has some limitations. Because the TMA approach, there could be heterogeneity in the pattern of FAK expression that accounted for these results as well. We also did not evaluate normal bronchial epithelium FAK expression and activation state which can be increased by exposure to cigarette smoke and thus hypothetically may potentially have prognostic impact on risk of local recurrences. 20 Another limitation is that because phosphorylated FAK cannot be measured reliably because of its labile nature and inherent variability in formalin-fixed paraffin-embedded specimen processing, we measured total FAK in this retrospective study which may There is no significant difference between overall survival and FAK expression in lung cancer. Log-rank curve and p values are shown for Figure 3A according to FAK score more than or equal to 3 and less than 3 and for Figure 3B according to FAK score more than or equal to 5 and less than 5.
not necessarily indicate an activated pathway. There may also be confounding variables found specifically in Asian patients that account for the lack of negative prognostic impact of FAK in our predominantly Caucasian population. The genomic changes found in NSCLC from Asian patients have a different profile from those found in patients from Western countries, even after controlling for histologic subtype. 21 These differences need to be studied in future investigations of the impact of FAK expression and lung cancer prognosis.
Despite the lack of prognostic value of FAK in stage I NSCLC, our report provides additional data for other investigators evaluating the role of FAK in lung carcinogenesis. Novel therapeutics to block FAK signaling is in development. Further understanding of the impact of modulating FAK in various stages of NSCLC will influence the clinical development of these agents and the corresponding trial design in the future.
